Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03449147 · ClinicalTrials.gov registry record · Phase 3
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,317
- Enrollment target
NCT03449147 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 1,317 participants.
The verdict
NCT03449147, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,317 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period, and to determine the safety and tolerability of gefapixant. The primary hypothesis is that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.
Interventions
- DRUG Placebo
- DRUG Gefapixant 15 mg BID
- DRUG Gefapixant 45 mg BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,317 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03449147
The ClinicalTrials.gov registry entry for NCT03449147 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03449147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03449147 about?
NCT03449147 is a clinical study titled "A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)". The primary objectives of this study are to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period, and to determine the safety and tolerability of gefapixant. The primary hypothesis is that at least one dose of gefapixant is superior to placebo i...
What is the current status of trial NCT03449147?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,317 participants. The study started on 2018-03-15. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03449147?
The interventions under investigation include: Placebo (DRUG), Gefapixant 15 mg BID (DRUG), Gefapixant 45 mg BID (DRUG).
Who is sponsoring clinical trial NCT03449147?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.